All In Biotech

Drug Trial Radar · NCT05164055

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

Jul 11, 2022

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This long-term open label safety and efficacy study is intended to follow up, and to provide post-trial access to ERT with avalglucosidase alfa to patients with Pompe disease in France who have completed Study EFC14028, LTS13769, or ACT14132, from market authorization until the conclusion of negotiations of avalglucosidase alfa in France under the standard reimbursement framework on each indication independently, infantile (IOPD) and late (LOPD), or until June 2027, whichever comes first. \- Study visit frequency: every 2 weeks

Conditions

  • Glycogen Storage Disease Type II

Interventions

  • Avalglucosidase alfa (GZ402666)Drug

    Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AE), treatment-emergent adverse events (TEAE), including infusion associated reactions (IAR) and deathTime frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 2500004

    Bordeaux, France

  • Investigational Site Number : 2500005

    Brest, France

  • Investigational Site Number : 2500008

    Clermont-Ferrand, France

  • Investigational Site Number : 2500009

    Lille, France

  • Investigational Site Number : 2500003

    Lyon, France

  • Investigational Site Number : 2500001

    Marseille, France

  • Investigational Site Number : 2500006

    Nantes, France

  • Investigational Site Number : 2500007

    Nice, France

  • Investigational Site Number : 2500002

    Paris, France

  • Investigational Site Number : 2500010

    Paris, France

  • Investigational Site Number : 2500011

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.